Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.41 |
| ▸ | ITGA2 | P17301 | 6/20 | 0.41 |
| ▸ | CTSD | P07339 | 6/20 | 0.40 |
| ▸ | CTSE | P14091 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878476 | 0.85 | BACE1 (0.46) | BACE1ITGB1ITGA2CTSDCTSE | |
| SCHEMBL4880797 | 0.81 | BACE1 (0.48) | BACE1CTSDCTSE | |
| SCHEMBL4880787 | 0.81 | BACE1 (0.48) | BACE1CTSDCTSE | |
| SCHEMBL4872651 | 0.69 | ITGB1 (0.41) | BACE1ITGB1ITGA2CTSDCTSE | |
| SCHEMBL4872647 | 0.69 | ITGB1 (0.41) | BACE1ITGB1ITGA2CTSDCTSE | |
| SCHEMBL2529554 | 0.67 | BACE1 (0.63) | BACE1CTSDCTSE | |
| SCHEMBL2527614 | 0.64 | BACE1 (0.68) | BACE1CTSDCTSE | |
| SCHEMBL2527616 | 0.64 | BACE1 (0.68) | BACE1CTSDCTSE | |
| SCHEMBL2530539 | 0.64 | BACE1 (0.71) | BACE1CTSDCTSE | |
| SCHEMBL4879112 | 0.63 | BACE1 (0.43) | BACE1CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | BACE1 1/4885ITGB1 3026/4885ITGA2 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.